Source: Owler

XBiotech, Inc.: XBiotech's revenue changed from $11.05M in Jun 2022 to $8.21M in Sep 2022

XBiotech’s Trailing Twelve Months revenue changed from $11.05M in Jun 2022 to $8.21M in Sep 2022 decreasing 25.7% in this time period.

Read full article »
XBiotech, Inc.'s Competitors | XBiotech, Inc.'s News | XBiotech, Inc.'s Financials

March 21, 2023

MarketScreener

Dupixent (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

(marketscreener.com) Approximately seven times as many patients aged 6 months to 5 years with severe ... See more »

March 21, 2023

Pharmabiz

Novartis shares Zolgensma longterm data demonstrating sustained durability up to 7.5 years postdosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma ... See more »

March 20, 2023

GlobeNewswire

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which pe... See more »
XBiotech's News
March 20, 2023Drug Discovery and Development

One-time gene therapy Zolgensma from Novartis shows lasting benefits for SMA patients

A gene therapy for spinal muscular atrophy (SMA) patients is making waves. Novartis (NYSE:NVS) reveal... See more »
XBiotech's News
March 21, 2023The Center for Biosimilar

FDA Approves Sandoz' High-Concentration Adalimumab Biosimilar, Hyrimoz

Sandoz set a launch date of July 1 for adalimumab-adaz injection, a citrate-free high-concentration b... See more »
XBiotech's News
March 21, 2023Benzinga

Laekna IPO Hopes To Hitch A Ride On Novartis Ties

Key Takeaways: Laekna has two main products, including one expected to file for approval in China and... See more »

March 21, 2023

MarketScreener

Dupixent (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

(marketscreener.com) Approximately seven times as many patients aged 6 months to 5 years with severe ... See more »

March 21, 2023

Pharmabiz

Novartis shares Zolgensma longterm data demonstrating sustained durability up to 7.5 years postdosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma ... See more »

March 20, 2023

GlobeNewswire

Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress

• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which pe... See more »
XBiotech's News
March 20, 2023Drug Discovery and Development

One-time gene therapy Zolgensma from Novartis shows lasting benefits for SMA patients

A gene therapy for spinal muscular atrophy (SMA) patients is making waves. Novartis (NYSE:NVS) reveal... See more »
XBiotech's News
March 21, 2023The Center for Biosimilar

FDA Approves Sandoz' High-Concentration Adalimumab Biosimilar, Hyrimoz

Sandoz set a launch date of July 1 for adalimumab-adaz injection, a citrate-free high-concentration b... See more »
XBiotech's News
March 21, 2023Benzinga

Laekna IPO Hopes To Hitch A Ride On Novartis Ties

Key Takeaways: Laekna has two main products, including one expected to file for approval in China and... See more »
Stay up-to-date with the latest news on XBiotech
Annual Revenue
$4M
Employees
100
John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating

80/100

Read more
Stay up-to-date with the latest news on XBiotech